Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201306025 Principal Investigator: Linette, Gerald
Title: Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination with Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase: I Disease Site: Melanoma, Skin
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to test what doses of the GSK study medications dabrafenib with or without trametinib can be given safely in combination with ipilimumab.
 
More Information:
ClinicalTrials.Gov Link
Internal Protocol Documents (requires Siteman administrative database password)